Cns Pharmaceuticals (US:CNSP) — Company Overview, News & Financial Data
Cns Pharmaceuticals is a biopharmaceutical company developing therapies for brain cancers, including glioblastoma treatment Berubicin.
Cns Pharmaceuticals
Cns Pharmaceuticals (NASDAQ:CNSP) focuses on the development of novel therapies for the treatment of brain and central nervous system cancers. A standout project in their pipeline is Berubicin, an anthracycline being evaluated for its potential to combat glioblastoma, one of the most aggressive types of brain cancer. Their objective is centered around advancing the clinical development of Berubicin to provide a new treatment option for patients faced with this devastating diagnosis. By investing rigorously in research and development, Cns Pharmaceuticals aims to break new ground in oncology, bringing hope and innovation to areas where current treatment options are limited.
Snapshot
Operations
Products and/or services of Cns Pharmaceuticals
- Berubicin, a novel anthracycline for the treatment of glioblastoma multiforme.
- WP1244, a DNA-binding agent targeting brain and other cancers.
- WP1122, a prodrug of 2-DG for potential treatment of COVID-19 and cancers.
- Collaboration with WPD Pharmaceuticals for the development of brain cancer therapies.
- Partnership for the advancement of novel oncology drug candidates.
- Engagement in clinical trials to evaluate the efficacy of novel cancer treatments.
Cns Pharmaceuticals executive team
- Mr. Christopher S. Downs CPA, CTP, FP&AChief Financial Officer
- Dr. Sandra L. Silberman M.D., Ph.D.Chief Medical Officer
- Mr. Rami Levin M.B.A.President, CEO & Director
- Dr. Donald H. Picker Ph.D.Chief Science Officer